• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 10-K/A filed by Embecta Corp. (Amendment)

    4/5/24 4:11:54 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care
    Get the next $EMBC alert in real time by email
    embc-20230930
    0001872789FY2023false00018727892022-10-012023-09-3000018727892023-03-31iso4217:USD00018727892023-11-20xbrli:shares


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 10-K/A
    Amendment No. 1
    ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    For the fiscal year ended September 30, 2023

    OR

    ☐
    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    For the transition period from _ to _

    Commission file number 001-41186
    embecta_rgb_sm.jpg
    EMBECTA CORP.
    (Exact name of registrant as specified in its charter)
    Delaware87-1583942
    (State or other jurisdiction of
    incorporation or organization)
    (I.R.S. employer
    identification no.)
    300 Kimball Drive, Suite 300, Parsippany, New Jersey
    07054
    (Address of principal executive offices)(Zip code)
    (862) 401-0000
    Registrant's telephone number, including area code
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class
    Trading
    symbol(s)
    Name of each exchange
    on which registered
    Common Stock, par value $0.01 per shareEMBC
    The Nasdaq Stock Market LLC (Nasdaq Global Select Market)
    Securities registered pursuant to Section 12(g) of the Act: None

    Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    Yes ☒ No ☐
    Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
    Yes ☐ No ☒



    Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐ 

    Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
    Yes  ☒   No  ☐ 
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
    Large accelerated filer☒Accelerated filer☐
    Non-accelerated filer☐
    Emerging growth company☐Smaller reporting company☐
                    
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. Yes ☒ No ☐

    If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

    Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

    Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).     Yes ☐   No  ☒
    The aggregate market value of the voting common equity held by non-affiliates of the registrant, computed by reference to the closing price at which the common stock was sold as of the end of the second fiscal quarter ended March 31, 2023, was approximately $1.6 billion.

    The registrant had outstanding 57,334,621 shares of common stock as of November 20, 2023.

    DOCUMENTS INCORPORATED BY REFERENCE
    The information required by Items 10, 11, 12, 13 and 14 of Part III of this Annual Report on Form 10-K is incorporated by reference to the Registrant’s definitive proxy statement for its 2024 Annual Meeting of Stockholders.
     




    EXPLANATORY NOTE
    Embecta Corp. (also referred to herein as the "Company") is filing this Amendment No. 1 to the Annual Report on Form 10-K (this “Form 10-K/A”) for the fiscal year ended September 30, 2023, originally filed with the Securities and Exchange Commission (the “SEC”) on November 29, 2023 (the “2023 Form 10-K” or “Original Filing”), solely for the purpose of correcting a scrivener’s error in the certifications filed as Exhibits 31.1 and 31.2 (the “Certifications”) to the 2023 Form 10-K. At the time the Company filed its 2023 Form 10-K, the Company’s certifying officers had completed the matters covered by paragraph 4(b) and the introductory language in paragraph 4 of the Certifications, referring to its internal control over financial reporting. The Certifications filed with the 2023 Form 10-K contained a scrivener’s error in that they inadvertently omitted such language, and the corrected Certifications are being filed as Exhibits 31.1 and 31.2 with this Form 10-K/A.
    Please note that the only changes to the Original Filing are those related to the matters described herein. Except as described above, no changes have been made to the Original Filing, and this Form 10-K/A does not modify, amend or update any of the other financial information or other information contained in the Original Filing, and except as specifically provided herein, this Form 10-K/A does not reflect any information or events occurring after the date of the Original Filing.





    PART IV
    Item 15. Exhibits and Financial Statement Schedules.
    (b) Exhibits
    Exhibit
    Number
    Exhibit Description
    31.1
    Certification of Chief Executive Officer, pursuant to SEC Rule 13a–14(a). (Filed herewith.)
    31.2
    Certification of Chief Financial Officer, pursuant to SEC Rule 13a–14(a). (Filed herewith.)
    104Cover Page Interactive Data File. (Formatted as Inline XBRL.)




    SIGNATURES
    Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

    EMBECTA CORP.
    By:/s/ JACOB ELGUICZE
    Name:Jacob Elguicze
    Title:Senior Vice President, Chief Financial Officer
    (Principal Financial Officer)
    Date: April 5, 2024


    Get the next $EMBC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EMBC

    DatePrice TargetRatingAnalyst
    4/10/2025$15.00Neutral
    Mizuho
    12/2/2024$13.00 → $20.00Underweight → Equal-Weight
    Morgan Stanley
    11/27/2024$26.00Neutral → Buy
    BTIG Research
    10/20/2023Peer Perform
    Wolfe Research
    1/6/2023$28.00Equal-Weight → Underweight
    Morgan Stanley
    9/8/2022Neutral
    BTIG Research
    8/1/2022$33.00Equal-Weight
    Morgan Stanley
    6/21/2022$25.00Underperform
    BofA Securities
    More analyst ratings

    $EMBC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Embecta Corp. Reports First Quarter Fiscal 2026 Financial Results

    PARSIPPANY, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today reported first quarter fiscal 2026 financial results. Visit the company's Investor Relations website at http://investors.embecta.com to view the detailed first quarter fiscal 2026 earnings press release and investor presentation. The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, February 5, 2026, which is accessible here, or access the teleconference here. A webcast replay of the call will be available be

    2/5/26 6:30:00 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    embecta Announces Quarterly Cash Dividend

    PARSIPPANY, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on March 17, 2026 to stockholders of record at the close of business on February 27, 2026. About embecta embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social

    2/5/26 6:00:00 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    embecta to Report Fiscal First Quarter Financial Results

    PARSIPPANY, N.J., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal first quarter 2026 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Thursday, February 5, 2026. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at investors.embecta.com. A webcast replay of the call will be available beginning at 11

    1/22/26 5:00:00 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $EMBC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mizuho initiated coverage on Embecta Corp. with a new price target

    Mizuho initiated coverage of Embecta Corp. with a rating of Neutral and set a new price target of $15.00

    4/10/25 12:41:09 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Embecta Corp. upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Embecta Corp. from Underweight to Equal-Weight and set a new price target of $20.00 from $13.00 previously

    12/2/24 6:56:10 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Embecta Corp. upgraded by BTIG Research with a new price target

    BTIG Research upgraded Embecta Corp. from Neutral to Buy and set a new price target of $26.00

    11/27/24 7:22:14 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $EMBC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Melcher David F bought $105,995 worth of shares (10,000 units at $10.60), increasing direct ownership by 13% to 86,681 units (SEC Form 4)

    4 - Embecta Corp. (0001872789) (Issuer)

    5/23/25 4:35:56 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Director Melcher David F bought $177,646 worth of shares (13,000 units at $13.67), increasing direct ownership by 20% to 76,681 units (SEC Form 4)

    4 - Embecta Corp. (0001872789) (Issuer)

    2/25/25 4:26:16 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Melcher David F bought $32,500 worth of shares (2,000 units at $16.25), increasing direct ownership by 5% to 45,080 units (SEC Form 4)

    4 - Embecta Corp. (0001872789) (Issuer)

    2/12/24 7:08:59 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $EMBC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by SVP, GC, Head Corp. Dev., Secy Mann Jeffrey Z

    4/A - Embecta Corp. (0001872789) (Issuer)

    12/3/25 4:48:42 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form 4 filed by SVP and CFO Elguicze Jacob

    4/A - Embecta Corp. (0001872789) (Issuer)

    12/3/25 4:45:38 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Chief Accounting Officer Roth Anthony M. was granted 32,817 shares and covered exercise/tax liability with 1,881 shares, increasing direct ownership by 188% to 47,415 units (SEC Form 4)

    4 - Embecta Corp. (0001872789) (Issuer)

    12/1/25 9:31:37 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $EMBC
    SEC Filings

    View All

    SEC Form 10-Q filed by Embecta Corp.

    10-Q - Embecta Corp. (0001872789) (Filer)

    2/5/26 11:26:03 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Embecta Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Embecta Corp. (0001872789) (Filer)

    2/5/26 6:54:42 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Embecta Corp.

    SCHEDULE 13G/A - Embecta Corp. (0001872789) (Subject)

    1/30/26 1:27:57 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $EMBC
    Leadership Updates

    Live Leadership Updates

    View All

    PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

    Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

    3/11/25 7:05:00 AM ET
    $BAX
    $BMRN
    $EMBC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Specialities

    Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

    Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of

    3/11/25 7:00:00 AM ET
    $BAX
    $BMRN
    $EMBC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Specialities

    Zimmer Biomet Announces Appointment of Devdatt Kurdikar to Board of Directors

    WARSAW, Ind., June 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Devdatt "Dev" Kurdikar, President, Chief Executive Officer and a member of the board of directors of Embecta Corp. (embecta), has been appointed to the Zimmer Biomet Board, effective immediately. embecta (NASDAQ:EMBC), formerly part of Becton, Dickinson and Company (BD), is one of the largest pure-play diabetes management companies in the world.  "We are pleased to welcome Dev to the ZB Board," said Chris Begley, Chairman of the

    6/20/24 7:30:00 AM ET
    $EMBC
    $ZBH
    Medical/Dental Instruments
    Health Care
    Industrial Specialties

    $EMBC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Embecta Corp.

    SC 13G/A - Embecta Corp. (0001872789) (Subject)

    11/8/24 10:57:43 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Embecta Corp.

    SC 13G/A - Embecta Corp. (0001872789) (Subject)

    11/7/24 4:21:15 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Embecta Corp.

    SC 13G - Embecta Corp. (0001872789) (Subject)

    10/25/24 5:45:30 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $EMBC
    Financials

    Live finance-specific insights

    View All

    Embecta Corp. Reports First Quarter Fiscal 2026 Financial Results

    PARSIPPANY, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today reported first quarter fiscal 2026 financial results. Visit the company's Investor Relations website at http://investors.embecta.com to view the detailed first quarter fiscal 2026 earnings press release and investor presentation. The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, February 5, 2026, which is accessible here, or access the teleconference here. A webcast replay of the call will be available be

    2/5/26 6:30:00 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    embecta Announces Quarterly Cash Dividend

    PARSIPPANY, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on March 17, 2026 to stockholders of record at the close of business on February 27, 2026. About embecta embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social

    2/5/26 6:00:00 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    embecta to Report Fiscal First Quarter Financial Results

    PARSIPPANY, N.J., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal first quarter 2026 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Thursday, February 5, 2026. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at investors.embecta.com. A webcast replay of the call will be available beginning at 11

    1/22/26 5:00:00 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care